{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:29Z","timestamp":1740106949713,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020957","name":"Roche Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We performed a molecular analysis of formalin-fixed paraffin embedded and decalcified bone marrow trephine biopsies of 41 patients with a B-cell disorder with lymphoplasmacytic differentiation to enable a more precise diagnosis and to describe potentially prognostic and therapeutic relevant mutations. Analysis was performed with a commercially available next-generation sequencing (NGS) lymphoma panel (Lymphoma Solution, SophiaGenetics). Results were correlated with clinical and pathological parameters. Our group covered a spectrum of B-cell disorders with plasmacytic differentiation ranging from Waldenstroem\u2019s macroglobulinemia (WM), to small-B-cell lymphomas with plasmacytic differentiation (SBCL-PC) to IgM myeloma (MM). The most helpful diagnostic criteria included morphology and immuno-phenotype as a prerequisite for the interpretation of molecular analysis. <jats:italic>MYD88<\/jats:italic> mutation was present in nearly all WM, but also in 50% of SBCL-PCs, while MM were consistently negative. Driver mutations, such as <jats:italic>TP53<\/jats:italic>, were already detectable early in the course of the respective diseases indicating a higher risk of progression, transformation, and reduced progression-free survival. In addition, we report on a novel BIRC3 frameshift mutation in one case of a progressive WM. Our data indicate that patients with LPL\/WM might benefit from thorough pathological work-up and detailed molecular analysis in terms of precise diagnosis and targeted treatment allocation.<\/jats:p>","DOI":"10.1007\/s00277-023-05531-9","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T17:01:41Z","timestamp":1699722101000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-4818","authenticated-orcid":false,"given":"Andrea","family":"Brunner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun Carolina","family":"Thalhammer-Thurner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Haun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina Gudrun","family":"Zelger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"issue":"1","key":"5531_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pathol.2019.09.009","volume":"52","author":"W Wang","year":"2020","unstructured":"Wang W, Lin P (2020) Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinaemia: clinicopathological features and differential diagnosis. Pathology 52(1):6\u201314","journal-title":"Pathology"},{"issue":"2","key":"5531_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al (2003) Clinicopathological definition of Waldenstrom\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol 30(2):110\u2013115","journal-title":"Semin Oncol"},{"issue":"2","key":"5531_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.26796","volume":"98","author":"MA Gertz","year":"2023","unstructured":"Gertz MA (2023) Waldenstrom macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol 98(2):348\u2013358","journal-title":"Am J Hematol"},{"issue":"4","key":"5531_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.5858\/arpa.2012-0034-RS","volume":"137","author":"N Naderi","year":"2013","unstructured":"Naderi N, Yang DT (2013) Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia. Arch Pathol Lab Med 137(4):580\u2013585","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"5531_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","volume":"35","author":"LM Kaiser","year":"2021","unstructured":"Kaiser LM, Hunter ZR, Treon SP, Buske C (2021) CXCR4 in Waldenstrom\u2019s macroglobulinema: chances and challenges. Leukemia 35(2):333\u2013345","journal-title":"Leukemia"},{"issue":"4","key":"5531_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/jha2.573","volume":"3","author":"P Garcia-Abellas","year":"2022","unstructured":"Garcia-Abellas P, Ferrer Gomez A, Bueno Sacristan D, PirisVillaespesa M, Talavera Yague M, RegueroCallejas ME et al (2022) Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: a diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis. EJHaem 3(4):1181\u20137","journal-title":"EJHaem"},{"issue":"3","key":"5531_CR7","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","volume":"102","author":"N Robillard","year":"2003","unstructured":"Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al (2003) CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102(3):1070\u20131071","journal-title":"Blood"},{"issue":"5","key":"5531_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1365-2141.2007.06969.x","volume":"140","author":"S Feyler","year":"2008","unstructured":"Feyler S, O\u2019Connor SJ, Rawstron AC, Subash C, Ross FM, Pratt G et al (2008) IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol 140(5):547\u2013551","journal-title":"Br J Haematol"},{"issue":"1","key":"5531_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2141.2008.07313.x","volume":"143","author":"E Willenbacher","year":"2008","unstructured":"Willenbacher E, Erdel M, Strasser U, Gastl G, Schmidt S, Gunsilius E et al (2008) IgM myeloma: more on a rare entity. Br J Haematol 143(1):146\u2013148","journal-title":"Br J Haematol"},{"issue":"6","key":"5531_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjh.12313","volume":"161","author":"W Willenbacher","year":"2013","unstructured":"Willenbacher W, Willenbacher E, Brunner A, Manzl C (2013) Improved accuracy of discrimination between IgM multiple myeloma and Waldenstrom macroglobulinaemia by testing for MYD88 L265P mutations. Br J Haematol 161(6):902\u2013904","journal-title":"Br J Haematol"},{"issue":"2","key":"5531_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ajh.24955","volume":"93","author":"JP Abeykoon","year":"2018","unstructured":"Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR et al (2018) MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol 93(2):187\u2013194","journal-title":"Am J Hematol"},{"issue":"3","key":"5531_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ajh.25697","volume":"95","author":"S Zanwar","year":"2020","unstructured":"Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S et al (2020) Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom macroglobulinemia. Am J Hematol 95(3):274\u2013281","journal-title":"Am J Hematol"},{"issue":"15","key":"5531_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R et al (2015) Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N Engl J Med 372(15):1430\u20131440","journal-title":"N Engl J Med"},{"issue":"11","key":"5531_CR14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","volume":"38","author":"SP Treon","year":"2020","unstructured":"Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X et al (2020) Genomic landscape of waldenstrom macroglobulinemia and its impact on treatment strategies. J Clin Oncol 38(11):1198\u20131208","journal-title":"J Clin Oncol"},{"issue":"10","key":"5531_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/17474086.2019.1649132","volume":"12","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP (2019) CXCR4 mutations affect presentation and outcomes in patients with Waldenstrom macroglobulinemia: a systematic review. Expert Rev Hematol 12(10):873\u2013881","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"5531_CR16","doi-asserted-by":"publisher","first-page":"E95","DOI":"10.1002\/ajh.25730","volume":"95","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML et al (2020) CXCR4 mutational status does not impact outcomes in patients with Waldenstrom macroglobulinemia treated with proteasome inhibitors. Am J Hematol 95(4):E95\u2013E98","journal-title":"Am J Hematol"},{"issue":"18","key":"5531_CR17","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G et al (2020) A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood 136(18):2038\u20132050","journal-title":"Blood"},{"issue":"3","key":"5531_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/bjh.16088","volume":"187","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE et al (2019) CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib. Br J Haematol 187(3):356\u2013363","journal-title":"Br J Haematol"},{"issue":"2","key":"5531_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjh.15560","volume":"184","author":"JN Gustine","year":"2019","unstructured":"Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X et al (2019) TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia. Br J Haematol 184(2):242\u2013245","journal-title":"Br J Haematol"},{"issue":"4","key":"5531_CR20","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/bjh.15909","volume":"186","author":"A Christian","year":"2019","unstructured":"Christian A, Davis Z, Walewska R, McCarthy H (2019) Importance of sequential analysis of TP53 variation in patients with Waldenstrom Macroglobulinaemia. Br J Haematol 186(4):e73\u2013e76","journal-title":"Br J Haematol"},{"issue":"20","key":"5531_CR21","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","volume":"23","author":"S Poulain","year":"2017","unstructured":"Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E et al (2017) TP53 mutation and its prognostic significance in Waldenstrom\u2019s macroglobulinemia. Clin Cancer Res 23(20):6325\u20136335","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5531_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.neo.2021.02.002","volume":"23","author":"Y Wang","year":"2021","unstructured":"Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM et al (2021) Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr\u00f6m macroglobulinemia. Neoplasia 23(4):361\u2013374","journal-title":"Neoplasia"},{"issue":"Suppl","key":"5531_CR23","first-page":"58","volume":"3","author":"SP Treon","year":"2019","unstructured":"Treon SP, Hunter ZR, Branagan AR, Castillo JJ (2019) Genomic landscape of Waldenstrom\u2019s macroglobulinemia. Hemasphere 3(Suppl):58\u201361","journal-title":"Genomic landscape of Waldenstrom's macroglobulinemia. Hemasphere"},{"issue":"12","key":"5531_CR24","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","volume":"102","author":"M Varettoni","year":"2017","unstructured":"Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L et al (2017) Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica 102(12):2077\u20132085","journal-title":"Haematologica"},{"issue":"1","key":"5531_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.15792","volume":"186","author":"E Willenbacher","year":"2019","unstructured":"Willenbacher E, Willenbacher W, Wolf DG, Zelger B, Peschel I, Manzl C et al (2019) Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88(L265P) detection in lymphomas with plasmacytic\/plasmacytoid differentiation. Br J Haematol 186(1):189\u2013191","journal-title":"Br J Haematol"},{"issue":"9","key":"5531_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/jclinpath-2019-206282","volume":"73","author":"J Garcia-Reyero","year":"2020","unstructured":"Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, Gomez Mediavilla A, Urquieta Lam M, Insunza A et al (2020) Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinaemia and description of its mutational profiles by targeted NGS. J Clin Pathol 73(9):571\u20137","journal-title":"J Clin Pathol"},{"issue":"9","key":"5531_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","volume":"5","author":"JN Mandrekar","year":"2010","unstructured":"Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 5(9):1315\u20131316","journal-title":"J Thorac Oncol"},{"issue":"2","key":"5531_CR28","first-page":"111","volume":"4","author":"S Safari","year":"2016","unstructured":"Safari S, Baratloo A, Elfil M, Negida A (2016) Evidence based emergency medicine; part 5 receiver operating curve and area under the curve. Emerg (Tehran) 4(2):111\u2013113","journal-title":"Emerg (Tehran)"},{"issue":"5","key":"5531_CR29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/10428194.2021.2018584","volume":"63","author":"K Amaador","year":"2022","unstructured":"Amaador K, Vos JMI, Pals ST, Kraan W, Dobber JA, Minnema MC et al (2022) Discriminating between Waldenstrom macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. Leuk Lymphoma 63(5):1070\u20131079","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"5531_CR30","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s00262-018-2242-9","volume":"67","author":"ANR Weber","year":"2018","unstructured":"Weber ANR, Cardona Gloria Y, \u00c7\u0131nar \u00d6, Reinhardt HC, Pezzutto A, Wolz OO (2018) Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities. Cancer Immunol Immunother 67(11):1797\u20131807","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"5531_CR31","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ajh.26339","volume":"96","author":"D Krzisch","year":"2021","unstructured":"Krzisch D, Guedes N, Boccon-Gibod C, Baron M, Bravetti C, Davi F et al (2021) Cytogenetic and molecular abnormalities in Waldenstr\u00f6m\u2019s macroglobulinemia patients: correlations and prognostic impact. Am J Hematol 96(12):1569\u20131579","journal-title":"Am J Hematol"},{"issue":"19","key":"5531_CR32","doi-asserted-by":"publisher","first-page":"11145","DOI":"10.3390\/ijms231911145","volume":"23","author":"AJ Boutilier","year":"2022","unstructured":"Boutilier AJ, Huang L, Elsawa SF (2022) Waldenstr\u00f6m macroglobulinemia: mechanisms of disease progression and current therapies. Int J Mol Sci 23(19):11145","journal-title":"Int J Mol Sci"},{"issue":"21","key":"5531_CR33","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","volume":"2","author":"ZR Hunter","year":"2018","unstructured":"Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C et al (2018) Insights into the genomic landscape of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia. Blood Adv 2(21):2937\u20132946","journal-title":"Blood Adv"},{"issue":"7247","key":"5531_CR34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459(7247):717\u2013721","journal-title":"Nature"},{"issue":"5","key":"5531_CR35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/modpathol.2011.213","volume":"25","author":"E Braggio","year":"2012","unstructured":"Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM et al (2012) Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol 25(5):651\u2013660","journal-title":"Mod Pathol"},{"issue":"1","key":"5531_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3816\/CLML.2011.n.021","volume":"11","author":"S Poulain","year":"2011","unstructured":"Poulain S, Braggio E, Roumier C, Aijjou R, Broucqsault N, Galiegue-Zouitina S et al (2011) High-throughput genomic analysis in Waldenstrom\u2019s macroglobulinemia. Clin Lymphoma Myeloma Leuk 11(1):106\u2013108","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"5531_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-018-0130-3","volume":"8","author":"K Wenzl","year":"2018","unstructured":"Wenzl K, Manske MK, Sarangi V, Asmann YW, Greipp PT, Schoon HR et al (2018) Loss of TNFAIP3 enhances MYD88. Blood Cancer J 8(10):97","journal-title":"Blood Cancer J"},{"issue":"10","key":"5531_CR38","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/modpathol.2017.58","volume":"30","author":"A Onaindia","year":"2017","unstructured":"Onaindia A, Medeiros LJ, Patel KP (2017) Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol 30(10):1338\u20131366","journal-title":"Mod Pathol"},{"issue":"2","key":"5531_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3324\/haematol.2019.238691","volume":"105","author":"E Tausch","year":"2020","unstructured":"Tausch E, Stilgenbauer S (2020) mutations in chronic lymphocytic leukemia - uncommon and unfavorable. Haematologica 105(2):255\u2013256","journal-title":"Haematologica"},{"issue":"2","key":"5531_CR40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3324\/haematol.2019.219550","volume":"105","author":"F Diop","year":"2020","unstructured":"Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A et al (2020) Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica 105(2):448\u2013456","journal-title":"Haematologica"},{"issue":"10","key":"5531_CR41","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1002\/ijc.33235","volume":"147","author":"C P\u00e9rez-Carretero","year":"2020","unstructured":"P\u00e9rez-Carretero C, Hern\u00e1ndez-S\u00e1nchez M, Gonz\u00e1lez T, Quijada-\u00c1lamo M, Mart\u00edn-Izquierdo M, Hern\u00e1ndez-S\u00e1nchez JM et al (2020) Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. Int J Cancer 147(10):2780\u20132792","journal-title":"Int J Cancer"},{"issue":"1","key":"5531_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-021-01032-2","volume":"14","author":"JS Walker","year":"2021","unstructured":"Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A et al (2021) Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J Hematol Oncol 14(1):17","journal-title":"J Hematol Oncol"},{"issue":"11","key":"5531_CR43","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1002\/ajh.24496","volume":"91","author":"P Jain","year":"2016","unstructured":"Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U et al (2016) Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478\u2013E479","journal-title":"Am J Hematol"},{"issue":"5","key":"5531_CR44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/ng.2584","volume":"45","author":"AJ Ramsay","year":"2013","unstructured":"Ramsay AJ, Quesada V, Foronda M, Conde L, Mart\u00ednez-Trillos A, Villamor N et al (2013) POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet 45(5):526\u2013530","journal-title":"Nat Genet"},{"issue":"4","key":"5531_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41374-018-0152-2","volume":"99","author":"SM El Jamal","year":"2019","unstructured":"El Jamal SM, Grada Z, El Dinali MH, Zhou H, Hassan SY, Saad AG et al (2019) MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type. Lab Invest 99(4):539\u2013550","journal-title":"Lab Invest"},{"issue":"10","key":"5531_CR46","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ni.2688","volume":"14","author":"CY Ying","year":"2013","unstructured":"Ying CY, Dominguez-Sola D, Fabi M, Lorenz IC, Hussein S, Bansal M et al (2013) MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol 14(10):1084\u20131092","journal-title":"Nat Immunol"},{"issue":"11","key":"5531_CR47","doi-asserted-by":"publisher","first-page":"e0241634","DOI":"10.1371\/journal.pone.0241634","volume":"15","author":"M Boiza-S\u00e1nchez","year":"2020","unstructured":"Boiza-S\u00e1nchez M, Manso R, Balagu\u00e9 O, Chamizo C, Askari E, Salgado RN et al (2020) Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: progression or divergent evolution? PLoS One 15(11):e0241634","journal-title":"PLoS One"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05531-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05531-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05531-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T08:03:46Z","timestamp":1705651426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05531-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["5531"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05531-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study on specimens of human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the ethical committee of the Medical University of Innsbruck (EK-Nr.1362\/2020) and informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}